Search | Clinical Trials Finder

Conditions: Healthy Volunteers
Interventions: rHuPH20, Insulin Human Injection, Insulin Lispro Injection; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin Aspart SAR341402, Insulin Aspart, Insulin glargine U100; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 33
States / cities: Concord, California • Temecula, California • Ventura, California + 30 more

Conditions: Diabetes, Hyperglycemia
Interventions: insulin glargine; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 30 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin glargine, Liraglutide, Metformin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 35 Years to 75 Years
Enrollment: 978 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 45
States / cities: Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 39 more

Conditions: Type 2 Diabetes Mellitus
Interventions: LY3209590, Insulin Degludec; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 31
States / cities: Sheffield, Alabama • Huntington Park, California • Los Angeles, California + 26 more

Conditions: Type 1 Diabetes Mellitus
Interventions: LY3209590, Insulin Degludec; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 33
States / cities: Concord, California • Fresno, California • Ventura, California + 29 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20), Liquid meal; Drug · Other
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Insulin Sensitivity
Interventions: Maltodextrin, Synbiotic, Sevelamer; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 65 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Shift Work Schedule, Circadian Rhythm, Insulin Resistance, Circadian Misalignment
Interventions: Metyrapone And Hydrocortisone, Dextrose, insulin; Drug
Lead sponsor: Washington State University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Healthy Volunteers, Diabetes Mellitus, Type 1
Interventions: LY2605541, Insulin glargine; Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: San Diego, California

Conditions: Frontotemporal Dementia, Behavioral Variant
Interventions: Novolin-R insulin; Drug
Lead sponsor: HealthPartners Institute; Other
Eligibility: 41 Years to 89 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Type 2 Diabetes Mellitus
Interventions: Insulin glargine/Lixisenatide; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 18
States / cities: Canyon Country, California • Huntington Park, California • Lomita, California + 13 more

Conditions: Type 2 Diabetes
Interventions: IcoSema, Insulin glargine; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 43
States / cities: Birmingham, Alabama • Concord, California • La Jolla, California + 37 more

Conditions: Type 2 Diabetes
Interventions: Exenatide, Glargine, Rapid-acting insulin analogs; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Type 1 Diabetes Mellitus
Interventions: Commercial Hylenex® recombinant (hyaluronidase human injection), Precommercial Hylenex recombinant (hyaluronidase human injection), Insulin lispro, Insulin aspart, Insulin glulisine; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 39
States / cities: Concord, California • Encino, California • Escondido, California + 35 more

Conditions: Type I Diabetes
Interventions: NNC0361-0041, Placebo; Drug · Other
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 16
States / cities: Orange, California • San Francisco, California • Stanford, California + 13 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Hyaluronidase, Control; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 12 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Stanford, California

Conditions: Type 1 Diabetes Mellitus
Interventions: Glucagon, Insulin; Drug
Lead sponsor: Legacy Health System; Other
Eligibility: 21 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Coronary Artery Disease
Interventions: Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart); Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 4
States / cities: Atlanta, Georgia

Conditions: Hyperglycemia
Interventions: Glucommander-Guided Intravenous Insulin Infusion, Standard Intravenous Insulin Infusion, Simple Calculated Intravenous Insulin Infusion; Procedure
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 80 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 3
States / cities: Chicago Heights, Illinois • Albuquerque, New Mexico

Conditions: Diabetes
Interventions: Hyperinsulinemic-hypoglycemic clamp; Procedure
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 40 Years
Enrollment: 4 participants
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Parkinson Disease, Multiple System Atrophy
Interventions: Intranasal Insulin; Drug
Lead sponsor: Peter Novak; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Glaucoma
Interventions: Insulin, 4 units, Insulin, 20 units, insulin, 4 units twice daily, insulin, 20 units twice daily, insulin, 4 units three times daily, insulin, 20 units three times daily; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Healthy Subjects
Interventions: TI Inhalation Powder; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Phoenix, Arizona

Search by objective public record fields.

Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20

Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine

Insulin Secretion in Diabetes Before and After Glycemic Control

Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure

A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus

A Study of LY3209590 in Participants With Type 1 Diabetes

Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus

Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim2)

Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance

A Study of LY2605541 Versus Insulin Glargine on Blood Sugar

Intranasal Insulin in Frontotemporal Dementia (FTD)

Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus

A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)

Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes

CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)

A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041

Hyaluronidase Effect on Infusion Set Life

Physiologic Response to Glucagon at Varying Insulin Levels

Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery

Comparative Trial Between 3 Types of Insulin Infusion Protocols

Use of a Hyperinsulinemic-hypyglycemic Clamp to Study Hypoglycemia: a Method Development Study

Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin.

Topical Insulin for Glaucoma

A Trial to Determine How Long Insulin and FDKP (the Molecule That Forms Technosphere Particles) Stays in the Lungs of Healthy Individuals After Inhalation of Technosphere® Insulin (TI) Powder Using Bronchoalveolar Lavage (BAL)